Cell therapy, T cell engagers, cancer vaccines and intratumoural therapy are turning biomarkers into eligibility gates, manufacturing inputs and response…
In vivo CAR-T programmes the patient's own T cells with a single IV dose, removing apheresis and manufacturing. Here is…
How spatial proteomics and spatial transcriptomics compare for immuno-oncology biomarker discovery: platforms, published evidence on checkpoint response, clinical translation hurdles…
The five immuno-oncology biomarker trends that will shape strategy, trial design and partnering in 2027, and what to look for…
A vendor-neutral comparison of soluble multiplex immunoassays and tissue multiplex immunofluorescence platforms for immuno-oncology biomarker teams, updated for the 2023…
A step-by-step guide to biomarker validation, from the context of use and fit-for-purpose analytical validation to clinical validation, clinical utility…
TMB-high at 10 mut/Mb became a tumour-agnostic indication in 2020, but the evidence since shows it predicts checkpoint benefit in…
A refreshed guide to PD-L1 testing: the four FDA companion assays, TPS, CPS and TC/IC scoring, current US cut-offs by…
300+ senior leaders. Two streams. One agenda: advancing precision oncology.
